Maintenance with Rituximab in anti-neutrophil cytoplasm antibody vasculitis
نویسندگان
چکیده
منابع مشابه
Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
The introduction of cyclophosphamide and high-dose glucocorticoids for anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) has allowed a reduction in 1-year mortality from 80% to 10-20%. AAV is now a chronic disease, and greater emphasis has turned to improving treatment-related toxicity, reducing relapses and providing alternative treatments for refractory disease. Rituximab,...
متن کاملRecommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
OBJECTIVES To perform a literature review and develop recommendations for the use of rituximab in ANCA-associated vasculitis. METHODS A committee of experts (five rheumatologists, five nephrologists and one paediatrician) conducted a modified Delphi exercise to identify five topics for a systematic literature search. The evidence was then reviewed, categorized according to international crite...
متن کاملRituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.
BACKGROUND AND OBJECTIVES Ongoing randomized trials seek to validate the efficacy of rituximab as an induction agent for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, no studies directly address the role of rituximab as maintenance therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This retrospective study reports the authors' experience with continuous...
متن کاملLong-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
OBJECTIVE Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be quite effective in the treatment of immune disorders resulting from autoantibodies. We prospectively studied the long-term effects of rituximab in 10 patients with anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis refractory to conventional therapy (n=3) or in second or subsequent relapse (n=7). ...
متن کاملImmunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
BACKGROUND Rituximab (RTX), a B cell-depleting anti-CD20 monoclonal antibody, is approved for treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Low immunoglobulin (Ig) levels have been observed surrounding RTX treatment. The association between the degree of Ig deficiency and infection risk is unclear in AAV patients. METHODS AAV patients treated with RTX f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vessel Plus
سال: 2020
ISSN: 2574-1209
DOI: 10.20517/2574-1209.2020.42